Personalised Antiemetic Prophylaxis with NEPA for Patients at High-Risk of Chemotherapy-induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial
{{output}}
Background: Patients receiving moderately emetogenic chemotherapy (MEC) are commonly prescribed a 5-HT3 receptor antagonist (RA) and dexamethasone (DEX) as standard of care (SOC) antiemetic prophylaxis. However, in patients with ... ...
